![](https://news.europawire.eu/wp-content/uploads/2013/12/novartis.jpg)
Novartis enters into an exclusive option agreement with Ionis and Akcea to license two investigational treatments expected to significantly reduce cardiovascular risk in patients living with elevated levels of lipoprotein Lp(a) or ApoCIII, which is a potent regulator of triglycerides … Read the full press release